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Research
AbstrACt
Objectives Our aim was to investigate the association of 
epigenetic age and physical capability in later life. Having 
a higher epigenetic than chronological age (known as age 
acceleration (AA)) has been found to be associated with 
an increased rate of mortality. Similarly, physical capability 
has been proposed as a marker of ageing due to its 
consistent associations with mortality.
setting The MRC National Survey of Health and 
Development (NSHD) cohort study.
Participants We used data from 790 women from the 
NSHD who had DNA methylation data available.
Design Epigenetic age was calculated using buccal cell 
(n=790) and matched blood tissue (n=152) from 790 
female NSHD participants. We investigated the association 
of AA at age 53 with changes in physical capability in 
women from ages 53 to 60–64. Regression models of 
change in each measure of physical capability on AA were 
conducted. Secondary analysis focused on the relationship 
between AA and smoking, alcohol, body mass index (BMI) 
and socioeconomic position.
Outcome measures Three objective measures of physical 
capability were used: grip strength, standing balance time 
and chair rise speed.
results Epigenetic age was lower than chronological age 
(mean 53.4) for both blood (50.3) and buccal cells (42.8). 
AA from blood was associated with a greater decrease in 
grip strength from ages 53 to 60–64 (0.42 kg decrease 
per year of AA, 95% CI 0.03, 0.82 kg; p=0.03, n=152), but 
no associations were observed with standing balance time 
or chair rise speed. Current smoking and lower BMI were 
associated with lower epigenetic age from buccal cells.
Conclusions We found evidence that AA in blood is 
associated with a greater decrease in grip strength in 
British females aged between 53 and 60–64, but no 
association with standing balance time or chair rise speed 
was found.
IntrODuCtIOn
There has been considerable recent interest 
in epigenetic biomarkers of ageing,1–6 which 
use an individual’s DNA methylation data 
to estimate their ‘epigenetic age’, a concept 
that could be considered a form of biological 
age. The Horvath age estimation method1 
found a correlation of 0.96 between chrono-
logical and epigenetic age, with individual 
estimates of epigenetic age within 3 years of 
chronological age on average. Epigenetic 
age has the potential to assess our biological 
age, but little is known about its relationship 
with our basic physiology. Moreover, several 
recent papers have found that the difference 
between epigenetic and chronological age 
(known as age acceleration, denoted AA) has 
biological significance. A positive AA indi-
cates an individual’s epigenetic age is ahead 
of their chronological age, a negative AA 
(ie, age deceleration) suggests an individual 
has younger epigenetic age than chronolog-
ical age. For example, positive AA has been 
found to be associated with obesity,7 Down’s 
syndrome,8 HIV,9 menopause10 and all-cause 
mortality.11 12 
Lower physical capability, assessed using 
objective measures such as grip strength, 
chair rise speed and standing balance time 
strengths and limitations of this study
 ► Our study is one of the first to examine epigenetic 
age from different tissues on the same individuals in 
relation toobjective measures of physical capability, 
which are key markers of healthy ageing.
 ► We used serial measures of physical capability on 
the same individuals over time, allowing for better 
inferences on changes in physical capability in late 
midlife, compared with having cross sectional data.
 ► A limitation of our findings is the lack of 
generalisability - the subsample of the cohort 
consisted of females only with repeated measures 
at ages 53 and 60-64 and was restricted to those 
with complete information on particular variables of 
interest (i.e. blood and buccal samples).
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have been found to be associated with all-cause mortality.13 
These findings, established through a systematic review of 
mainly older populations, were also observed using data 
on physical capability in midlife from the MRC National 
Survey of Health and Development (NSHD),14–16 which 
has followed 5362 individuals born in the same week of 
March 1946.
It is pertinent to understand the mechanisms under-
pinning the association between epigenetic age and 
mortality, since epigenetics are a potentially modifiable 
risk factor. A recent study identified a cross-sectional asso-
ciation between epigenetic AA and lower grip strength in 
an older population using data from the Lothian Birth 
Cohort 193617. There was no strong evidence for links 
between epigenetic AA and changes in grip strength, 
lung function or cognition from age 70 to 76. More recent 
studies have reported no evidence between epigenetic 
age and either cognitive18 or composite measures of 
biomarker19 of ageing. In the present article, we sought to 
investigate the associations between epigenetic AA at age 
53 and objective measures of physical capability at ages 
53 and 60–64 in the NSHD. We hypothesised that individ-
uals with positive AA (ie, with epigenetic age higher than 
expected based on a linear regression of epigenetic age 
on chronological age) would have lower average physical 
capability scores and greater declines than those with 
lower epigenetic age. We also use data from the NSHD to 
investigate whether increased epigenetic age is associated 
with mortality risk factors; smoking,20 higher body mass 
index (BMI)21 22 and more disadvantaged socioeconomic 
position (SEP).23
MethODs
study participants
DNA was first collected in NSHD participants at age 
5324 in 1999; following quality control (QC), the study 
sample with epigenetic information available consisted of 
790 women who had a buccal cell sample taken at age 
53 (mean age 53.4, SD 0.16, range 53–54), and who had 
complete information on epidemiological variables of 
interest and follow-up. Among these 790 women, there 
were 152 who also had epigenetic information available 
from blood at age 53. These 152 were originally selected 
for a case-control study of cancer, and consisted of 75 inci-
dent cancer cases after age 53 and 77 controls randomly 
selected from those with complete data available for the 
cancer study.16 25 26 Mortality risk factor data were available 
at age 53 on smoking status (current, never or ex-smoker), 
nurse measured height (cm) and weight (kg) (used to 
calculate BMI (kg/m2)). Childhood SEP was indicated by 
father’s occupational class and SEP in adulthood by own 
occupational social class at 53 and educational qualifica-
tions by age 26. Father’s occupational class and own occu-
pational class in adulthood were each defined according 
to the Registrar General’s social classification: unskilled, 
partly skilled, skilled (manual), skilled (non-manual), 
intermediate or professional. Education level attained 
was classified as none, vocational, sub-General Certificate 
of Secondary Education (GCSE), O level, A level, degree 
or higher.
study outcomes
The three measures of physical capability were grip 
strength (kg), standing balance time (s) and chair rise 
time (s) measured at age 53 and again at age 60–64 by 
nurses using standardised protocols.27 Grip strength was 
ascertained isometrically using an electronic dynamom-
eter which was calibrated using a back-loading rig and 
was stable to within 0.5 kg. Two values from each hand 
were recorded at 53, and three in each hand at 60–64, 
with the maximum of the first four values at each age 
used for analysis. The standing balance test recorded the 
times that participants could stand on one leg up to a 
maximum of 30 s first with eyes open and then repeated 
with eyes closed. Balance times with eyes closed were used 
for analysis and these were log transformed to reduce 
skewness. Chair rise time was measured using a stopwatch 
and recorded as the time taken to rise from a seated 
position to a standing position with a straight back and 
legs followed by a return to a seated position as fast as 
possible, repeated 10 times. Chair rise speed was then 
calculated by dividing the number of rises (ie, 10) by the 
time taken in minutes. This was done to make high scores 
correspond to good performance, as for the other two 
measures. Nurses recorded whether the participant was 
unwilling or unable to perform each of the tests along 
with the reason for this.
Composite capability scores were generated by 
combining performance on grip strength, balance time 
and chair rise speed using methods previously described.14 
In brief, each measure was rescaled to a 0 (low) to 1 (high) 
scale before aggregation into a composite score from 
0 to 3 at ages 53 and 60–64. Standing balance time was 
rescaled by dividing by 30 s (the maximum time allowed); 
height adjusted grip strength and chair rise time were 
rescaled by dividing by the 99th percentile. Those unable 
to carry out a test for health reasons were assigned a score 
of 0 for that test.
DnA methylation data
DNA methylation was measured using the Infinium 
HumanMethylation450 BeadChip (Illumina) in NSHD 
participants who had biological samples collected in 
1999; 638 (buccal cell only) and 152 (buccal cell and 
blood).25 QC and normalisation was performed on each 
of the 790 buccal samples and then separately on the 
152 matched whole blood samples. For each, the minfi 
package was used to process raw idat data files,28 using 
the Illumina definition of beta-values and extracting p 
values of detection for each sample. The Illumina meth-
ylation beta-value of a given CpG site is found from the 
intensity of the methylated (M) and unmethylated (U) 
alleles, as the ratio of fluorescent signals β=Max(M,0)/
[Max(M,0)+Max(U,0)+100]. The level of methylation is 
expressed as a ‘beta’ value (β-value), ranging from 0 (no 
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cytosine methylation) to 1 (complete cytosine methyla-
tion). As a further QC step, probes that contained <95% 
of signals detectable above background signal (detection 
p<0.01) were removed from further analysis, and the rest 
of missing values were imputed using the k-nearest neigh-
bours imputation procedure.29 To correct for the well-
known bias of type 2 probes, we used the subset-quantile 
within normal array package.30 To check robustness of 
this correction procedure, we verified that results were 
largely unchanged using beta mixture quantile normali-
station.31 This completed the intrasample normalisation. 
All participants provided written informed consent. The 
Central Manchester Ethics Committee approved the use 
of these samples for epigenetic studies of health.
epigenetic age
Using the online epigenetic clock calculator (http:// labs. 
genetics. ucla. edu/ horvath/ dnamage), we obtained DNA 
methylation estimated age using the Horvath1 method. 
The raw DNA methylation β-values were generated from 
the 152 blood and 790 buccal cell samples. Along with 
epigenetic age, the online calculator estimates raw AA 
differences (epigenetic minus chronological age) and 
AA residuals (the residuals from a linear regression of 
epigenetic age on chronological age). Our main expo-
sure of interest is the latter AA residual, which we will call 
AA. AA values from blood were corrected for estimated 
cell type heterogeneity using the Houseman method.32 
The Houseman estimated cell counts were included in 
the regression of epigenetic age on chronological age to 
get cell count adjusted AA.
statistical analysis
Median absolute error was used to investigate the relation-
ship between chronological age and epigenetic age from 
blood and buccal tissue, with correlation being secondary 
given the low range of actual age in NSHD. Changes in 
each physical capability measure were considered the 
main outcomes, with the differences in grip strength, chair 
rise speed, balance time and composite score from age 53 
to age 60–64 being used for analysis. Using this uncon-
ditional change model allows us to directly compare our 
results with those from the Lothian Birth Cohort 193617. 
The differences were regressed on AA from blood and 
buccal tissue separately. We fitted unadjusted regression 
models followed by models adjusted for age, height and 
BMI and then additionally adjusted for smoking and both 
childhood and adult SEP. Linear regression was also used 
to test the association of AA (from both blood and buccal 
cells) at age 53 with each physical capability measure 
and the composite score at both ages 53 and 60–64. As a 
secondary analysis with AA as the outcome, we carried out 
unadjusted regression analysis of the known mortality risk 
factors of height, BMI, smoking and SEP (both childhood 
and adult).
In a sensitivity analysis, we reran the main models with 
inclusion of those women who were unable to perform 
each of the three physical capability tests for health 
reasons (table 1 includes percentage unable to perform 
each task). To enable their inclusion, women who were 
unable to complete a test for health reasons were allo-
cated the minimum value observed at either age.
replication
Findings were tested for replication using cross-sectional 
data from the mothers of the Avon Longitudinal Study of 
Parents and Children (ALSPAC).33 34 ALSPAC recruited 
14 541 pregnant women with expected delivery dates 
between April 1991 and December 1992. Of these initial 
pregnancies, there were 14 062 live births and 13 988 chil-
dren who were alive at 1 year of age. The study website 
contains details of all the data that are available through 
a fully searchable data dictionary (http://www. bris. ac. 
uk/ alspac/ researchers/ data- access/ data- dictionary). 
DNA methylation and epigenetic age were available from 
988 ALSPAC mothers at mean age of 46.9 (SD 4.7 years, 
range 31–60) as part of the Accessible Resource for Inte-
grated Epigenetics Studies (ARIES) project.35 The ARIES 
study is a subsample of ALSPAC, which generated DNA 
methylation for 1000 families who had biological samples 
available at each of five time points: umbilical cord blood 
at birth, peripheral blood at age 7 and 17 in children 
and peripheral blood during pregnancy and at 18 years 
follow-up for mothers. The 1000 families were randomly 
selected from those who had full data available. We used 
the mother’s follow-up data to replicate our analysis 
because they best reflected the available NSHD women. 
All DNA methylation wet-lab and preprocessing analyses 
were performed at the University of Bristol as part of the 
ARIES project. Following extraction, DNA was bisulphite 
converted using the Zymo EZ DNA MethylationTM kit 
(Zymo, Irvine, California, USA). Infinium HumanMethyl-
ation450 BeadChips were used to measure genome-wide 
DNA methylation levels at over 485 000 CpG sites. The 
arrays were scanned using an Illumina iScan, with initial 
quality review using GenomeStudio. The assay detects 
methylation of cytosine at CpG islands using two site-spe-
cific probes—one to detect the methylated (M) locus and 
one to detect the unmethylated (U) locus. Single-base 
extension of the probes incorporates a labelled chain-ter-
minating ddNTP, which is then stained with a fluores-
cence reagent. The ratio of fluorescent signals from the 
methylated site versus the unmethylated site determines 
the level of methylation at the locus. The level of methyl-
ation is expressed as a β-value, ranging from 0 (no cyto-
sine methylation) to 1 (complete cytosine methylation). 
β-Values are reported as percentages.
Grip strength, balance time and chair rise speed along 
with height, BMI, smoking and SEP (adulthood only) 
were available from these same women. Grip strength was 
assessed using the Jamar handgrip dynamometer and was 
recorded to the nearest 1 kg using both the right and left 
hands. Two measures were taken in each hand and the 
maximum of these values was used. In the chair rise test, 
the participant was asked to rise from a sitting position to 
a straight-legged fully standing position five times while 
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Table 1 Descriptive statistics for continuous variables
Continuous variable Age when measured Mean (SD) N N unable (%)
Age (years) 53 53.44 (0.16) 790 –
64 63.09 (1.09) 623 –
Epigenetic age from buccal (years) 53 42.83 (5.71) 790 –
Age acceleration from buccal (years) 53 0.00 (5.66) 790 –
Epigenetic age from blood (years) 53 50.28 (4.34) 152 –
Age acceleration from blood (years) 53 0.00 (4.34) 152 –
Height (cm) 53 161.43 (5.61) 790 –
BMI (kg/m2) 53 28.13 (6.43) 784 –
64 29.10 (7.50) 622 –
Grip strength (kg) 53 28.18 (8.15) 767 18 (2)
64 25.71 (7.94) 575 21 (3)
Grip strength change (kg) 64 −2.62 (8.53) 560
Chair rise speed (stands/min) 53 30.98 (9.56) 737 40 (5)
64 24.54 (7.82) 577 40 (5)
Chair rise speed change (stands/min) 64 −6.87 (10.07) 556
Balance time (log-seconds) 53 1.77 (0.60) 734 32 (8)
64 1.52 (0.55) 593 24 (3)
Balance time change (log-seconds) 64 −0.27 (0.68) 561 –
Composite score 53 1.31 (0.33) 750 –
64 1.19 (0.37) 591 –
Composite score change 64 −0.13 (0.36) 558 –
Categorical variable Age when measured Category N (%)
Smoking 53 Never 384 (49)
Ex 239 (30)
Current 167 (21)
Childhood SEP 53 Professional 57 (7)
Intermediate 160 (21)
Skilled (non-manual) 123 (16)
Skilled (manual) 245 (31)
Partly skilled 148 (19)
Unskilled 48 (6)
Adult SEP 53 Professional 14 (2)
Intermediate 261 (33)
Skilled (non-manual) 286 (36)
Skilled (manual) 57 (7)
Partly skilled 119 (15)
Unskilled 50 (7)
Education 53 None 275 (35)
Vocational 44 (5)
Sub-GCE 38 (5)
O level 201 (26)
A level 106 (14)
Burham A2 75 (10)
Degree 32 (4)
Postgraduate 2 (1)
BMI, body mass index; GCE, General Certificate of Education; SEP, socioeconomic position.
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being timed. Chair rise speed was then calculated by 
dividing five by the total time required. This differs from 
NSHD in having five total stands, although most of the 
between-study variability would be resolved by using chair 
rise speed rather than total time taken. In the balance 
time test, the participant stood next to a table and asked 
to choose a leg and raise it off the floor to ankle height. 
The participant was timed until they lost their balance 
and dropped their foot or had to reach out to the table 
for support. If the participant remained on one leg for 
longer than 30 s, they were stopped. The process was 
repeated with eyes closed, which was used for analysis to 
mirror the NSHD measure.
results
The descriptive statistics are displayed in table 1. The 
average epigenetic age was 42.8 (SD 5.71 years) using 
DNA methylation from buccal tissue and 50.3 (SD 4.34 
years) using DNA methylation from blood. These both 
underestimate the average chronological age of 53.4 
years (SD 0.16 years). The median absolute error between 
chronological and epigenetic age is 10.5 and 4.1 years for 
buccal and blood, respectively. Correlation with chrono-
logical age was much lower than previously reported: 
0.022 (p=0.79) for blood age and 0.115 (p=0.16) for 
buccal age, but this correlation is a less appropriate 
assessment due to the narrow age range (SD of age=0.16 
years). Correlation was slightly higher between the two 
epigenetic ages, with a Pearson correlation coefficient of 
0.190 (p=0.02).
AA, being the residual of a regression of epigenetic age 
on chronological age, has a mean close to zero by defi-
nition. However, the variance and range are larger for 
AA of buccal tissue compared with blood tissue. Average 
levels of each physical capability measure changed in the 
expected direction, with a mean decrease in grip strength 
of 2.6 kg (SD 8.5 kg), chair rise speed of 6.8 stands/min 
(SD 10.1 stands/min) and balance time of 0.27 log-sec-
onds (SD 0.68 log-seconds) from age 53 to 60–64. This 
is reflected in an average decrease of 0.12 units in the 
composite score for physical capability.
Age acceleration and physical capability
Change in physical capability
For a 1 year increase in AA, grip strength decreased by an 
additional 0.42 kg (95% CI 0.03 to 0.82 kg; p=0.03) from 
age 53 to 60–64 after adjusting for height, BMI, educa-
tion and SEP (table 2). There was no strong evidence 
for an association between AA and change in chair rise 
speed (0.06 higher stands/min per 1 year AA 95% CI 
−0.40 to 0.52 stands/min; p=0.80) or balance time (0.01 
log-seconds lower per 1 year AA, 95% CI −0.04 to 0.02 
log-seconds; p=0.55). The weak associations of AA from 
buccal cells and physical capability were in the expected 
direction.
Separate analysis of physical capability measured at 53 and 
60–64
There were no associations between physical capability at 
age 53 and epigenetic AA, either from blood or buccal 
samples (online supplementary table S1). Effect sizes 
were much smaller in buccal AA compared with blood AA 
for grip strength and particularly for chair rise speed. The 
associations of AA with grip strength, balance time and 
the composite score were positive, indicating greater AA 
was associated with better performance, that is, the oppo-
site direction to that expected. Similarly, there was little 
evidence for an association between epigenetic age and 
any of the physical capability markers or the composite 
score at age 60–64 (online supplementary table S2). Here, 
the effect of AA was in the expected negative direction 
for grip strength, chair rise speed and balance time, with 
stronger effects observed from blood AA than buccal AA.
Age acceleration and mortality risk factors
There were positive associations between BMI at age 53 
and AA from buccal tissue: 0.085 (95% CI 0.014 to 0.156; 
p=0.02) years of AA per 1 kg/m2 increase in BMI. The 
strength of association was lower for blood tissue: 0.044 
years of AA per 1 kg/m2 change in BMI (95% CI −0.065 
to 0.154 years; p=0.42) (table 3). There was no associa-
tion between height and AA. We observed an association 
between smoking and AA of buccal tissue (p=0.001), but 
not in blood tissue. Current smokers had the lowest AA 
on average, with ex-smokers and never-smokers having 
1.88 (95% CI 0.85 to 2.9) and 1.85 (95% CI 0.76 to 3.0) 
extra years of AA, respectively. AA did not vary by child-
hood or adult SEP.
sensitivity analysis
We provide associations of AA and change in physical capa-
bility when including imputed data for those unable to 
perform tests in online supplementary table S3. Including 
individuals unable to perform the grip strength test atten-
uates its association with AA. For a 1 year increase in AA, 
grip strength decreased by an additional 0.29 kg (95% CI 
−0.74 to 0.15 kg; p=0.19) from age 53 to 60–64 in a fully 
adjusted model. Including individuals unable to perform 
tasks did not dramatically affect any of the other blood 
AA or buccal associations.
replication
Using data from 988 ALSPAC women with mean age 
46.9, we attempted to replicate the cross-sectional find-
ings from NSHD (tables 4 and 5). The median absolute 
error and correlation between epigenetic and chronolog-
ical age was 3.9 years and 0.53 in ALSPAC, respectively, 
where the chronological age was 47.4 (SD 4.5 years, range 
34.5–60). AA was not related to grip strength, chair rise 
speed or balance time. The finding that higher BMI was 
associated with greater AA was replicated in the ALSPAC 
women (0.129 years per 1 kg/m2 increase in BMI, 95% CI 
0.051 to 0.207 years, p=0.001) but smoking was not asso-
ciated with AA (p=0.43), although the direction of effect 
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was the same, with ex-smokers having 0.56 years higher 
AA and never smokers 0.17 years higher AA compared 
with current smokers on average. As in NSHD, height and 
education were not associated with AA.
DIsCussIOn
Age acceleration in blood is associated with a greater 
decline in grip strength from age 53 to 60–64; for every 
1 year of AA, women had a 0.4 kg greater decrease in 
grip strength. Neither blood nor buccal epigenetic age 
acceleration at age 53 was associated with grip strength or 
other measures of physical capability at either age 53 or 
60–64. The epigenetic age calculated in our sample was 
systematically lower than chronological age, particularly 
for buccal cells (mean difference of 10.7 years for buccal 
cells).
Our study is one of the first to examine epigenetic age 
from different tissues on the same individuals in relation 
to risk factors for mortality. We used serial measures of 
physical capability on the same individuals over time, 
allowing for better inferences on changes in physical 
capability in late midlife, compared with having just 
cross-sectional data. However, one limitation is having 
just two measures, which are susceptible to regression 
to the mean. A limitation of our findings is the lack of 
generalisability—the subsample of the cohort consisted 
of females only with repeated measures at ages 53 and 
64 and was restricted to those with complete information 
on particular variables of interest (ie, blood and buccal 
samples). The 790 women sampled here had marginally 
lower grip strength (25.7 vs 26.0 kg, p=0.4) and chair rise 
speed (24.5 vs 25.5 stands/min, p=0.007) than NSHD 
Table 2 Association of age acceleration with changes in physical capability from age 53 to 64 in NSHD participants
Variable Model*
Blood (n=152) Buccal (n=790)
Regression 
coefficient 
(difference 
per year AA) 95% CI p Value
Regression 
coefficient 
(difference 
per year AA) 95% CI p Value
Grip strength 
(kg)
Unadjusted −0.34 −0.70 to 0.01 0.06 −0.02 −0.16 to 0.12 0.73
Adjusted for age, 
height, BMI
−0.33 −0.69 to 0.02 0.06 −0.03 −0.17 to 0.12 0.73
Adjusted for height, 
BMI, smoking, 
education and SEP
−0.42 −0.82, to 0.03 0.03 −0.07 −0.22 to 0.08 0.35
Chair rise speed 
(stands/min)
Unadjusted 0.20 −0.23 to 0.62 0.37 −0.03 −0.17 to 0.12 0.70
Adjusted for age, 
height, BMI
0.19 −0.24 to 0.62 0.38 −0.04 −0.19 to 0.10 0.58
Adjusted for height, 
BMI, smoking, 
education and SEP
0.06 −0.40 to 0.52 0.80 −0.05 −0.20 to 0.10 0.53
Balance time, 
eyes closed 
(log-seconds)
Unadjusted −0.01 −0.04 to 0.02 0.38 −0.001 −0.011 to 0.010 0.92
Adjusted for age, 
height, BMI
−0.01 −0.04 to 0.02 0.39 −0.002 −0.012 to 0.009 0.76
Adjusted for height, 
BMI, smoking, 
education and SEP
−0.01 −0.04 to 0.02 0.55 −0.002 −0.012 to 0.009 0.73
Composite 
score
Unadjusted −0.01 −0.028 to 0.003 0.10 0.001 −0.005 to 0.007 0.77
Adjusted for age, 
height, BMI
−0.01 −0.028 to 0.003 0.11 0.000 −0.005 to 0.006 0.87
Adjusted for height, 
BMI, smoking, 
education and SEP
−0.01 −0.03 to 0.01 0.16 −0.001 −0.007 to 0.005 0.68
AA, age acceleration; BMI, body mass index; SEP, socioeconomic position.
*For each of the four physical capability outcome measures, we ran three models, first unadjusted, then adjusted for height and BMI, then 
adjusted for height, BMI, smoking, education and both adult and childhood SEP.
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women overall at age 60–64.36 Including those individ-
uals who were unable to perform the grip strength test 
attenuated the association with blood AA. Although 18 
and 21 grip strength tests could not be performed at age 
53 and 60–64, respectively (table 1), just 6 of these were 
from individuals with blood DNA methylation available. 
The attenuation was mainly due to a single individual 
with low AA and high grip strength at age 53 who was 
unable to perform the test at age 60–64. Our results 
should be viewed with consideration for multiple testing. 
Our primary analysis includes epigenetic age acceleration 
from two tissues tested against four measures of physical 
capability, giving a total of eight tests. This diminishes the 
strength of the evidence provided by this study.
Our blood results should be compared with another 
recent study of epigenetic age and physical capability in 
an older UK birth cohort.17 Using data from the Lothian 
Birth Cohort 1936, cross-sectional associations at age 70 
were found between greater epigenetic age and weaker 
grip strength as well as with lower lung function and 
cognitive capability, but not walking speed; however, 
they found no association between baseline epigenetic 
age and changes in either physical or cognitive capa-
bility from age 70 to 76. We have found some evidence 
that epigenetic age measured at 53 may be associated 
with a greater decline in grip strength between age 53 
and 60–64, but no associations were identified with any 
physical capability measure at age 53 or 60–64. In the 
Table 3 Associations of mortality risk factors with outcome of age acceleration (years) at 53 for NSHD participants*
Variable Level
Blood (n=152) Buccal (n=790)
Regression 
coefficient 
(difference per 
year AA) 95% CI p Value
Regression 
coefficient 
(difference per 
year AA) 95% CI p Value
Height (cm) −0.017 −0.085 to 0.051 0.63 −0.011 −0.14 to 0.11 0.86
BMI 53 (kg/m2) 0.085 0.014 to 0.16 0.02 0.044 −0.065 to 0.15 0.42
Smoking Current Reference 0.001 Reference 0.42
Ex-smoker 1.88 0.85 to 2.91 0.83 −0.99 to 2.66
Never 1.86 0.76 to 2.95 −0.16 −2.17 to 1.85
Childhood SEP Professional Reference 0.80 Reference 0.56
Intermediate −0.73 −2.44 to 0.99 −1.30 −4.01 to 1.40
Skilled (non-
manual)
−0.81 −2.59 to 0.97 −0.48 −3.24 to 2.27
Skilled 
(manual)
−0.25 −1.89 to 1.38 −1.24 −3.88 to 1.39
Partly skilled −0.94 −2.67 to 0.79 −0.11 −2.90 to 2.67
Unskilled −0.40 −2.57 to 1.78 1.39 −2.40 to 5.17
Adult SEP Professional Reference 0.62 Reference 0.35
Intermediate 0.95 −2.11 to 4.01 −1.65 −10.27 to 6.97
Skilled (non-
manual)
0.95 −2.10 to 4.00 −1.95 −10.59 to 6.69
Skilled 
(manual)
1.35 −1.97 to 4.68 −0.25 −9.13 to 8.63
Partly skilled 0.032 −3.12 to 3.18 −3.41 −12.31 to 5.50
Unskilled 0.52 −2.85 to 3.89 0.24 −8.73 to 9.22
Education None Reference 0.78 Reference 0.64
Vocational 0.16 −1.65 to 1.98 −1.25 −4.72 to 2.22
Sub-GCSE 1.20 −0.73 to 3.14 −1.74 −5.21 to 1.73
O level 0.41 −0.63 to 1.45 −1.02 −2.90 to 0.86
A level −0.53 −1.81 to 0.75 −1.97 −4.29 to 0.35
Burham A2 0.55 −0.91 to 2.00 −1.43 −3.66 to 0.81
Degree −0.28 −2.36 to 1.81 −2.01 −5.73 to 1.71
Postgraduate −0.81 −8.73 to 7.11 0.84 −0.38 to 2.06
*AA, age acceleration; BMI, body mass index; GCSE, General Certificate of Secondary Education; NSHD, National Survey of Health and 
Development; SEP, socioeconomic position.
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Lothian Birth Cohort, the reported effect size of AA on 
grip strength at age 70 was −0.05 kg per year of blood 
AA with a sample size of 100.17 In our analysis, the effect 
sizes at age 53 and 60–64 were 0.18 and −0.15 kg per year 
of blood AA, respectively with a sample size of 152. The 
relatively small sample in our analysis of blood AA may 
mean our study lacks the required power, or it could 
be that this association only manifests at older ages. It 
is possible that the association is beginning to emerge 
in NSHD at age 60–64 (an age still younger than the 
Lothian Birth Cohort baseline), with the suggestion of 
faster rates of change in those with greater AA. We do 
not, however, observe any associations between buccal 
cell AA and physical capability where we have a larger 
sample size and more comparable statistical power to the 
Lothian Birth Cohort. Our different results could also be 
due to sex differences between the two studies; the LBC 
includes both men and women, whereas we have only 
looked in females. Several studies have identified higher 
AA in men than in women.37 To better understand the 
epigenetic embodiment of physical capability in later 
life, one might perform epigenome-wide analysis of 
these measures.
The weak correlations found between epigenetic and 
chronological ages (0.022 for blood, 0.115 for buccal 
cells) should be considered with the knowledge that the 
SD of age is 0.16 years (range 53–54 years). Horvath,1 
using data from across 82 studies, compared the SD of age 
measured in each study with the correlation coefficient 
found in each study between epigenetic and chronolog-
ical age. He found a correlation of 0.49 between the SD 
of age and the performance of his epigenetic clock (in 
terms of correlation). Thus, with such a small age range in 
our sample, it should be no surprise that we find a dimin-
ished correlation. In ALSPAC, by comparison, where the 
SD of age is larger at 4.5 years, the correlation between 
epigenetic and chronological age is 0.53. Comparing the 
median absolute error the difference is much smaller, 
with 4.1 years in NSHD and 3.9 years in ALSPAC. This 
suggests that while the correlation metric is not suitable 
Table 4 Replication of physical capability and age acceleration in ALSPAC mothers with mean age 46.9
Variable Model*
Regression coefficient 
(difference per year AA) 95% CI p Value
Grip strength (kg) Unadjusted −0.021 −0.12 to 0.078 0.68
Adjusted for height, BMI −0.044 −0.14 to 0.052 0.37
Adjusted for height, BMI, SEP −0.034 −0.13 to 0.065 0.50
Chair rise speed (stands/min) Unadjusted 0.0004 −0.0004 to 0.001 0.31
Adjusted for height, BMI 0.0005 −0.0003 to 0.001 0.22
Adjusted for height, BMI, SEP 0.0004 −0.0004 to 0.001 0.31
Balance time, eyes closed 
(log-seconds)
Unadjusted 0.067 −0.058 to 0.19 0.30
Adjusted for height, BMI 0.083 −0.045 to 0.21 0.20
Adjusted for height, BMI, SEP 0.088 −0.042 to 0.22 0.18
AA, age acceleration; ALSPAC, Avon Longitudinal Study of Parents and Children; BMI, body mass index; SEP, socioeconomic position.
*For each of the four physical capability measures, we ran three models, first unadjusted, then adjusted for height and BMI, then adjusted for 
height, BMI, smoking and education.
Table 5 Replication of mortality risk factors with outcome of age acceleration in ALSPAC mothers with mean age 46.9
Variable Level Association with AA (years) 95% CI p Value
Height (cm) 0.0288 −0.034 to 0.092 0.37
BMI (kg/m2) 0.1293  0.051 to 0.21 0.001
Smoking Current Reference 0.43
Ex 0.5605 −0.88 to 2.00
Never 0.1693 −1.90 to 2.24
Education Secondary Reference 0.28
Vocational 0.1693 −1.90 to 2.24
O level 0.2586 −1.34 to 1.86
A level −0.0295 −1.65 to 1.59
Degree 1.2266 −0.47 to 2.93
AA, age acceleration; ALSPAC, Avon Longitudinal Study of Parents and Children; BMI, body mass index.
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for NSHD, the epigenetic clock itself is valid for blood 
samples.
While the epigenetic clock was trained on observations 
from individuals from newborn to 100 years of age, it is 
likely that age-specific clocks could improve on Horvath’s 
clock. However, these benefits are negated by the loss of 
generalisability. It is also required that the relationship 
between chronological age and epigenetic age is linear. In 
our sample, there is no evidence against a linear relation-
ship, and the residuals from this model of epigenetic age 
on chronological age, that is, the age accelerations them-
selves, were normally distributed in this older population.
While the very small range of age at which the epigen-
etic information was taken in our sample explains the low 
correlation, it does not explain the bias when using the 
buccal samples. The systematic difference found here 
appears to be related to tissue specificity, since epigen-
etic age from blood was closer to chronological age than 
buccal epigenetic age. The Horvath age estimator was 
developed using publicly available data covering 51 tissue 
types (including buccal cells) such that tissue specificity 
should not result in such an underestimate of chronolog-
ical age. Three sets of publicly available buccal cell DNA 
methylation data38–40 were among those used in the devel-
opment of the Horvath epigenetic clock, with a reported 
correlation of 0.9 between chronological and buccal 
epigenetic age.1 However, these were from 109 adoles-
cents,38 30 newborns (ie, 10 pairs of monozygotic (MZ) 
and 5 pairs of dizygotic (DZ) twins between birth and 
18 months40) and 10 individuals who were aged 16, 27, 
28, 29, 37, 42, 44, 44, 52, 6839. The systematic difference 
(of 10.7 years) may be explained by the lack of overlap in 
the age at which information from buccal cells was avail-
able in our study and those in the training dataset used to 
derive the epigenetic clock. Our study questions the use 
of the epigenetic clock for buccal samples in females aged 
between 53 and 60–64.
There are a growing number of studies comparing 
DNA methylation from more than one tissue on the same 
group of individuals,10 25 41 with one of these using the 
same NSHD data as the current study.10 One novel appli-
cation of the epigenetic clock is to estimate epigenetic 
ages from different tissues on the same individuals. In 
the current study, we have found evidence that buccal 
samples are epigenetically younger than blood samples in 
a UK population. We found a weak correlation between 
epigenetic age from blood and buccal cells in the same 
individuals (r=0.19). This low correlation may be due 
to residual confounding. Since the blood samples come 
from a case-control study within the birth cohort from 
which the 790 buccal samples were taken, it may be that 
the poor correlation between tissues is attributable to 
selection bias. Further comparisons of epigenetic ages 
from different tissue types in the same individuals may 
elucidate our findings.
We found both lower BMI and smoking were related 
to age deceleration, with the BMI finding replicated in 
blood methylation age from ALSPAC women at mean age 
46.9. Previous research has found this same association 
between higher BMI and AA in liver tissue,7 37 but ours is 
the first finding in buccal cells. Our finding that smoking 
is associated with lower AA is unexpected, since previous 
research suggests that positive blood AA is associated with 
higher rates of mortality.11 This could be due to our use 
of buccal cells, which are likely more reflective of the 
effect of smoking on DNA methylation.25 It is currently 
unknown whether buccal AA is associated with mortality, 
nor if the direction is the same as blood AA. Further to 
this point, the smoking and AA association was not seen 
in blood samples from ALSPAC or NSHD participants, 
suggesting this particular result may be spurious.
In conclusion, having a higher epigenetic than chrono-
logical age is associated with a greater decline in grip 
strength in British females aged between 53 and 60–64, 
but overall there is little evidence that AA is associated 
with physical capability change in these women. AA does 
not appear to be related to measures of physical capa-
bility in women at ages 53 or 60–64, while BMI appears 
to be associated with accelerated epigenetic age in this 
population.
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